Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

Exscientia和牛津大学宣布合作开发治疗阿尔茨海默病的方法

2021-02-11 21:32:37 BioSpace

本文共3161个字,阅读需8分钟

Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer’s disease medicines that alleviate the burden of devastating disease OXFORD, England--(BUSINESS WIRE)-- Exscientia, a leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD). AD is the most common form of dementia worldwide, with an estimated 44 million people living with AD or related form of dementia.1,2 Symptoms of this progressive disease are debilitating, distressing – for both those with the disease and their loved ones – and there is currently no cure.3 This exciting new partnership unites Exscientia's AI-driven molecular design capabilities with the deep therapy area knowledge and technical expertise of the ARUK-ODDI. The collaboration will focus on a specific neuroinflammatory pathway implicated in the development of AD. Activation of the NLRP3 inflammasome has been shown to have an important role in AD pathogenesis and, while there have been other efforts to develop anti-inflammatory drugs for AD,4 targeting NLRP3 inflammasome inhibition in the brain is an innovative therapeutic approach. Exscientia’s proven AI-driven technology will be applied to efficiently generate high-value novel clinical assets targeting this pathway. Feeding into this are chemical starting points that modulate NLRP3 inflammasome formation identified over years of research by the ARUK-ODDI. Coupling Exscientia's Centaur Chemist® AI-design systems with the ARUK-ODDI’s biology and screening expertise is expected to speed up delivery of distinct candidate molecules for AD. Exscientia’s COO David Hallett commented: “Alzheimer’s is a dreadful disease that affects tens of millions worldwide. Despite clinical trials of numerous agents over a wide range of mechanisms, the last new Alzheimer’s medication, was approved nearly two decades ago. Alzheimer’s drug development is costly, complex and extremely challenging with clinical trial failure rate being the highest of any therapeutic area. Our mission is to make novel drugs available to all and we are excited to utilise our AI drug discovery platform and work alongside the expertise of the Alzheimer’s Research UK-Oxford Drug Discovery Institute team to accelerate innovation and develop potential medicines to solve this global epidemic.” Expanding on this new relationship, Dr John Davis, CSO of the Alzheimer’s Research UK-Oxford Drug Discovery Institute drew attention to the benefits gained from the complementary capabilities of both partners: "We are delighted to be partnering with Exscientia. Their state-of-the-art AI capabilities will enable us to investigate multiple molecules in parallel and accelerate the project towards candidate declaration. Human genetic variation points towards a critical role for the body’s immune system in an individual’s risk of developing Alzheimer’s disease. It is vital that we develop treatments that target neuroinflammatory mechanisms underlying dementia.” Dr Sara Imarisio, Head of Research at Alzheimer’s Research UK said: “Scientist’s at our ARUK-Oxford Drug Discovery Institute are ideally placed to capitalise on the latest discoveries and work with partners to help translate this into drugs that could be tested in clinical trials. With nearly one million people in the UK living with dementia, there isn’t a moment to waste.” ENDS Notes to Editors: About the NLRP3 inflammasome in the pathophysiology of Alzheimer’s disease (AD) Inflammasomes are part of the innate immune system and are responsible for a wide range of inflammatory responses. In AD, activated NLRP3 inflammasome leads to the release of pro-inflammatory cytokine (IL-1 beta) and ASC (apoptosis-associated speck-like protein containing a caspase-recruitment domain) speck into the intercellular space. The release of ASC specks from microglia promotes amyloid-beta aggregation in AD. The accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together result in neurodegeneration and cognitive decline that characterize AD. About Exscientia Exscientia is an Artificial Intelligence (AI)-driven pharmatech, committed to discovering medicines in the fastest and most effective manner for patients. As a clinical stage company, Exscientia is the first to progress AI-designed small molecules into a clinical setting, demonstrating the ability of AI to transform the pharmaceutical industry. Drug design is precision engineering at the molecular scale. To transform the industry, Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently re-apply enhanced knowledge through iterations of design. Because Exscientia’s AI systems learn more rapidly and effectively than human-led efforts, candidate molecules satisfying complex therapeutic requirements are discovered with revolutionary efficiency. Exscientia puts AI at the centre of its strategy to revolutionise drug discovery, designing therapeutics for areas of high unmet need, that will positively impact patients. About Centaur Chemist® Centaur Chemist® is Exscientia’s solution to AI-driven drug design combining the latest AI-tech with the therapeutic experience of seasoned drug hunters. Driven by algorithms that mimic evolutionary design as well as deep learning to analyse complex information and active learning to extract insights from sparce, high-value datasets, Centaur Chemist® has been skilfully engineered to work with widest range of discovery data to ensure application to the widest range of discovery projects. Centaur Biologist® Centaur Biologist® supports the discovery and prioritisation of drug targets, ensuring that any candidate molecules developed will be aligned with key therapeutic objectives. With deep learning and vector embedding techniques Centaur Biologist® pinpoints trends and insights from big data and captures semantics that predict new unexpected associations. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI About the ARUK-Oxford Drug Discovery Institute, University of Oxford The Alzheimer’s Research UK Oxford Drug Discovery Institute is a drug discovery team, founded with funding from the charity Alzheimer’s Research UK, with the objective of accelerating the translation of basic science generated within universities towards therapeutic utility. The focus of the team is upon discovering treatments for the neurodegenerative diseases underlying dementia. Although Alzheimer’s disease is the most common cause of dementia and the charity bears its name, the remit of the ARUK-ODDI covers all diseases and mechanisms implicated in the different neurodegenerative diseases that contribute to dementia, including Alzheimer’s disease, Parkinson’s disease, vascular dementia and frontotemporal dementia. For more information, visit https://oxford-ddi.alzheimersresearchuk.org/about-the-institute/. References: 1 World Health Organization. Fact Sheet. Dementia. Available at: https://www.who.int/news-room/fact-sheets/detail/dementia. Last accessed 10 February 2021 2 Alzheimer’s News Today. Available at: https://alzheimersnewstoday.com/alzheimers-disease-statistics/. Last accessed 10 February 2021 3 NHS. Alzheimer’s Disease. Available at: https://www.nhs.uk/conditions/alzheimers-disease/. Last accessed 10 February 2021 4 Immunity’s flipside: Microglia promote Alzheimer’s pathology during inflammation. Available at: https://www.novusbio.com/antibody-news/immunitys-flipside-microglia-promote-alzheimers-pathology-during-inflammation. Last accessed 10 February 2021 View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005386/en/ PR Contacts: For Exscientia Mark Swindells, Chief Commercial Officer contact@exscientia.ai Anitra Sprauten, Edelman anitra.sprauten@edelman.com +44 (0)78 9685 9386 Source: Exscientia View this news release online at: http://www.businesswire.com/news/home/20210211005386/en
针对炎症体的神经炎症合作--在阿尔茨海默病的竞争中加快步伐,减轻毁灭性疾病负担的药物 英国牛津--(商业电讯)--领先的人工智能药物研发公司Exscientia今天宣布,它与英国牛津大学药物研发研究所(ARUK-ODDI)的阿尔茨海默氏病研究机构合作,开发针对神经炎症的药物,用于治疗阿尔茨海默氏病(AD)。 AD是世界范围内最常见的痴呆形式,估计有4400万人患有AD或相关形式的痴呆。1,2这种进展性疾病的症状使人虚弱、痛苦--对患者及其所爱的人来说都是如此--而且目前尚无治愈方法。3 这一令人振奋的新伙伴关系将ExScientia的AI驱动的分子设计能力与Aruk-Oddi的深度治疗领域知识和技术专长结合起来。 该合作将集中于AD发展中的一种特定神经炎症通路。NLRP3炎症体的激活已被证明在AD的发病机制中具有重要作用,尽管已经有其他的努力来开发AD的抗炎药物,但靶向脑内NLRP3炎症体抑制是一种创新的治疗方法。 ExScientia公司经过验证的AI驱动技术将被应用于高效生成针对这一途径的高价值新型临床资产。通过Aruk-Oddi多年来的研究发现,调节NLRP3炎症体形成的化学起始点被注入其中。ExScientia公司的半人马座化学家®AI设计系统与Aruk-Oddi公司的生物学和筛选专业技术相结合,有望加快AD独特候选分子的交付。 ExScientia的首席运营官大卫·哈利特评论说:“阿尔茨海默氏症是一种可怕的疾病,影响着全世界数千万人。尽管对多种机制的药物进行了临床试验,但最后一种新的老年痴呆症药物是在近20年前获得批准的。阿尔茨海默病的药物开发成本高、复杂且极具挑战性,临床试验失败率是所有治疗领域中最高的。我们的使命是让所有人都能获得新型药物,我们很高兴能利用我们的人工智能药物发现平台,并与英国-牛津药物发现研究所阿尔茨海默氏症研究团队的专业技术合作,加速创新,开发潜在的药物,以解决这一全球流行病。“ 英国-牛津药物发现研究所阿尔茨海默氏病研究中心的CSO约翰·戴维斯博士在拓展这一新的合作关系时提请注意双方互补能力所带来的好处:“我们很高兴与ExScientia公司合作。他们最先进的人工智能能力将使我们能够同时研究多个分子,并加速项目的候选申报。人类基因变异指向人体免疫系统在个体患阿尔茨海默氏病风险中的关键作用。至关重要的是,我们开发针对痴呆症潜在神经炎症机制的治疗方法。” 英国阿尔茨海默氏病研究中心的研究负责人萨拉·伊马里西奥博士说: “我们阿鲁克-牛津药物发现研究所的科学家处于利用最新发现的理想位置,并与合作伙伴合作,帮助将这些发现转化为可进行临床试验的药物。英国有近一百万人患有痴呆症,因此一刻也不能浪费。“ 结束 编辑注意事项: NLRP3炎症体在阿尔茨海默病(AD)病理生理中的作用 炎症体是先天免疫系统的一部分,负责广泛的炎症反应。在AD中,活化的NLRP3炎症体导致促炎性细胞因子(IL-1 beta)和含有半胱天冬酶招募域的凋亡相关斑点样蛋白(apoptosis associated speck-like protein controlling a caspase-restructure domain,ASC)向细胞间隙释放斑点。从小胶质细胞释放ASC斑点促进AD的淀粉样蛋白-beta聚集。斑块中淀粉样蛋白-beta的积聚、过度磷酸化的tau在神经原纤维缠结中的聚集和神经炎症共同导致AD的神经变性和认知功能下降。 关于Exscientia Exscientia是一家人工智能(AI)驱动的药明康德,致力于为患者以最快、最有效的方式发现药物。作为临床阶段公司,Exscientia率先将AI设计的小分子进展到临床设置,展示了AI改造医药行业的能力。 药物设计是分子尺度上的精密工程。为了改变这个行业,Exscientia建立了专门的AI系统,这些系统能够有效地从最广泛的数据中学习,并通过迭代设计不断地重新应用增强的知识。由于ExScientia的AI系统比人类主导的努力学习得更快更有效,满足复杂治疗需求的候选分子以革命性的效率被发现。 Exscientia将人工智能置于其战略的中心,以革命性的药物发现,为高需求领域设计疗法,这将对患者产生积极影响。 关于半人马化学家® Centaur化学家®是ExScientia将最新的AI技术与经验丰富的药物猎手的治疗经验相结合的AI驱动药物设计解决方案。在模拟进化设计的算法以及分析复杂信息的深度学习和从sparce高价值数据集中提取洞察力的主动学习的驱动下,半人马座化学家®被巧妙地设计成能够处理最广泛的发现数据,以确保应用于最广泛的发现项目。 半人马生物学家® 半人马座生物学家®支持药物靶点的发现和优先排序,确保开发的任何候选分子都将与关键的治疗目标对齐。利用深度学习和向量嵌入技术,半人马座生物学家®从大数据中精确定位趋势和洞察力,并捕捉语义,预测新的意想不到的关联。 欲了解更多信息,请访问www.exscientia.ai或在Twitter@exscientiaai上关注我们 关于牛津大学阿鲁克-牛津药物发现研究所 英国阿尔茨海默氏症研究牛津药物发现研究所是一个药物发现小组,由慈善机构英国阿尔茨海默氏症研究资助成立,其目标是加速将大学内产生的基础科学转化为治疗用途。研究小组的重点是发现痴呆的神经退行性疾病的治疗方法。虽然阿尔茨海默病是痴呆症最常见的原因,慈善机构也以它的名字命名,但阿鲁克-奥迪协会的职权范围涵盖了导致痴呆症的各种神经退行性疾病所涉及的所有疾病和机制,包括阿尔茨海默病、帕金森病、血管性痴呆症和额颞叶痴呆症。欲了解更多信息,请访问https://oxford-ddi.alzheimersresearchuk.org/about-the-institute/。 参考资料: 1世界卫生组织。概况介绍。痴呆。查阅网址:https://www.who.int/news-room/fact-sheets/detail/dementia。最后访问2021年2月10日 2老年痴呆症今日新闻。查阅网址:https://alzheimersnewstoday.com/alzheimers-disease-statistics/。最后访问2021年2月10日 3 NHS。老年痴呆症。查阅网址:https://www.nhs.uk/conditions/alzheimers-disease/。最后访问2021年2月10日 4免疫方面:小胶质细胞在炎症过程中促进阿尔茨海默病病理。网址:https://www.novusbio.com/antibody-news/immunitys-flipside-microglia-promot-alzheimers-pathology-wide-interfacty。最后访问2021年2月10日 在businesswire.com上查看源版本:https://www.businesswire.com/news/home/20210211005386/en/ 公关联系人: 对于Exscientia Mark Swindells,首席商务官 contact@exscientia.ai 埃德尔曼·阿尼特拉·斯普劳滕 电子邮件:anitra.sprauten@edelman.com +44(0)78 968 5 938 6 资料来源:Exscientia 请在以下网址联机查看此新闻稿: http://www.businesswire.com/news/home/20210211005386/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文